IPOBoutique.Com rates secondary offerings to hit the tape with a \u2018BUY\u2019, \u2018NEUTRAL\u2019 or \u2018AVOID\u2019 rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary\u2019s he\u2019s issued with a \u2018BUY\u2019 rating. <\/p>\n
Company: \tBioPharmx Company: \tTransEnterix, Inc. Company: \tAmicus Therapeutics Company: \tPapa Murphy’s Holdings, Inc. Company: \tGlobal Partners LP Company: \tNielsen N.V. Company: \tActivision Blizzard, Inc.-BLOCK Company: \tCommScope Holding Company, Inc.
\nSymbol: \tBPMX
\nPrice: \t\t$3.00-$3.00
\nDescription: \tThey are a specialty pharmaceutical company focused on utilizing our proprietary drug delivery technologies to develop and commercialize novel prescription and over-the-counter, or OTC, products that address large markets in women’s health and dermatology. Their common stock is presently quoted on the OTCQB Marketplace under the symbol $BPMX. On April 8, 2015, the last reported sale price of shares of our common stock on the OTCQB Marketplace was $3.00 per share.
\nTrade Date: \t6\/11
\nShares: \t5 million
\nUnderwriter(s) \tCRT Capital
\nCo Manager(s)\tFeltl and Company, Newport Coast Securities Inc.
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tTRXC
\nPrice: \t\tLast trade $3.45
\nTrade Date: \t6\/12
\nShares: \t14.1 million
\nUnderwriter(s) \t Stifel, RBC Capital Markets
\nCo Manager(s)\tRaymond James, BTIG
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tFOLD
\nPrice: \t\tLast trade $13.09
\nTrade Date: \t6\/12
\nShares: \t11.5 million
\nUnderwriter(s) \tJ.P. Morgan, Goldman Sachs, Cowen & Co.
\nCo Manager(s)\tJanney Montgomery Scott
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tFRSH
\nPrice: \t\tLast trade $18.57
\nTrade Date: \t6\/11
\nShares: \t2 million
\nUnderwriter(s) \tJefferies
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tGLP
\nPrice: \t\tLast trade $39.93
\nTrade Date: \t6\/11
\nShares: \t3 million
\nUnderwriter(s) \tBarclays, BofA Merrill Lynch, Wells Fargo Securities, Deutsche Bank, J.P. Morgan, Raymond James
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tNLSN
\nPrice: \t\tLast trade $45.22
\nTrade Date: \t6\/11
\nShares: \t8.9 million
\nUnderwriter(s) \tGoldman Sachs
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tATVI
\nPrice: \t\tLast trade $25.50
\nTrade Date: \t6\/11
\nShares: \t36.2 million
\nUnderwriter(s) \tBarclays
\nRating=Subscription Needed<\/a><\/p>\n
\nSymbol: \tCOMM
\nPrice: \t\tLast trade $32.42
\nTrade Date: \t6\/11
\nShares: \t20 million
\nUnderwriter(s) \tJ.P. Morgan
\nRating=Subscription Needed<\/a><\/p>\n